LBS 008

Drug Profile

LBS 008

Alternative Names: LBS008

Latest Information Update: 02 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Columbia University
  • Developer Columbia University; Lin Bioscience
  • Class Eye disorder therapies
  • Mechanism of Action RBP4 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Stargardt disease
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Dry age-related macular degeneration; Stargardt disease

Most Recent Events

  • 27 Oct 2017 LBS 008 receives Orphan Drug status for Stargardt disease 1 in USA
  • 26 Oct 2017 Lin BioScience plans a phase I trial for Dry age-related macular degeneration in USA
  • 26 Oct 2017 Lin BioScience plans a phase I trial for Stargardt disease in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top